1. Home
  2. CRBP vs INLX Comparison

CRBP vs INLX Comparison

Compare CRBP & INLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • INLX
  • Stock Information
  • Founded
  • CRBP 2009
  • INLX 1996
  • Country
  • CRBP United States
  • INLX United States
  • Employees
  • CRBP N/A
  • INLX N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • INLX EDP Services
  • Sector
  • CRBP Health Care
  • INLX Technology
  • Exchange
  • CRBP Nasdaq
  • INLX Nasdaq
  • Market Cap
  • CRBP 73.4M
  • INLX 60.5M
  • IPO Year
  • CRBP N/A
  • INLX N/A
  • Fundamental
  • Price
  • CRBP $6.03
  • INLX $13.13
  • Analyst Decision
  • CRBP Strong Buy
  • INLX
  • Analyst Count
  • CRBP 10
  • INLX 0
  • Target Price
  • CRBP $60.89
  • INLX N/A
  • AVG Volume (30 Days)
  • CRBP 207.2K
  • INLX 6.9K
  • Earning Date
  • CRBP 05-06-2025
  • INLX 05-13-2025
  • Dividend Yield
  • CRBP N/A
  • INLX N/A
  • EPS Growth
  • CRBP N/A
  • INLX N/A
  • EPS
  • CRBP N/A
  • INLX N/A
  • Revenue
  • CRBP N/A
  • INLX $18,018,373.00
  • Revenue This Year
  • CRBP N/A
  • INLX $8.12
  • Revenue Next Year
  • CRBP $150.00
  • INLX N/A
  • P/E Ratio
  • CRBP N/A
  • INLX N/A
  • Revenue Growth
  • CRBP N/A
  • INLX 6.70
  • 52 Week Low
  • CRBP $4.64
  • INLX $5.85
  • 52 Week High
  • CRBP $61.90
  • INLX $16.50
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 49.07
  • INLX 52.55
  • Support Level
  • CRBP $5.68
  • INLX $12.58
  • Resistance Level
  • CRBP $6.29
  • INLX $13.39
  • Average True Range (ATR)
  • CRBP 0.46
  • INLX 0.66
  • MACD
  • CRBP 0.19
  • INLX -0.06
  • Stochastic Oscillator
  • CRBP 84.24
  • INLX 26.24

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

Share on Social Networks: